Stockscreener 앱 받기
5.59
0.18%
0.010
시장 영업 전:
5.48
-0.11
-1.97%
Mannkind Corp 주식(MNKD)의 최신 뉴스
MannKind stock gets Buy rating reaffirmation from Truist at $9 target - Investing.com
Avant Technologies Leads Transformation in Healthcare Market - Intellectia AI
MannKind (NASDAQ:MNKD) Receives Buy Rating from HC Wainwright - MarketBeat
HC Wainwright & Co. Reiterates 'Buy' Rating for MNKD with $11 Target | MNKD Stock News - GuruFocus
MannKind Announces FDA Approval of Updated Afrezza Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy - Finviz
MNKD Stock Gets A Pre-Market Boost From FDA Label Revision For Afrezza - Stocktwits
Why Did MNKD Stock Jump Over 7% In Pre-Market Today? - Asianet Newsable
MannKind stock rises after FDA approves updated Afrezza label - Investing.com
FDA approves updated dosing guidelines for MannKind’s inhaled insulin - Investing.com
MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy - Yahoo Finance
MannKind’s Volatile Week: Can MNKD Justify The Recent Rebound In Its Stock? - AD HOC NEWS
Growth Report: What hedge funds are buying MannKind CorporationJuly 2025 Levels & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets - GlobeNewswire Inc.
Investment Recap: Is MannKind Corporation backed by strong institutional buying - baoquankhu1.vn
Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema - Finviz
Will 2026 FDA Decisions on Afrezza and FUROSCIX Redefine MannKind's (MNKD) Narrative - Yahoo Finance
MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know - Finviz
Short Interest in MannKind Corporation (NASDAQ:MNKD) Grows By 26.1% - MarketBeat
MannKind Corporation (MNKD) Reveals 2026 Growth Drivers - Insider Monkey
MannKind (NASDAQ:MNKD) Shares Down 6.4%Here's What Happened - MarketBeat
Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia - Finviz
CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why - Finviz
Evaluating MannKind (MNKD) Valuation After Recent Share Price Swings And Long Term Return Profile - Yahoo Finance
TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results - Finviz
MannKind (NASDAQ:MNKD) Raised to Strong-Buy at Zacks Research - MarketBeat
MannKind (MNKD) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
Deltec Asset Management LLC Takes $3.89 Million Position in MannKind Corporation $MNKD - MarketBeat
Mannkind’s chief people officer sells $297k in stock By Investing.com - Investing.com Australia
MannKind Corporation (NASDAQ:MNKD) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Insider Sell: Stuart Tross Sells 47,006 Shares of MannKind Corp (MNKD) - GuruFocus
Mannkind’s chief people officer sells $297k in stock - Investing.com
MannKind Corp stock hits 52-week high at 6.33 USD By Investing.com - Investing.com Nigeria
Pharma news weekly roundup - The Pharma Letter
Is MannKind Corporation stock affected by interest rate hikesMarket Trend Review & Consistent Profit Alerts - ulpravda.ru
How MannKind Corporation stock reacts to Fed rate cutsJuly 2025 Snapshot & Safe Swing Trade Setups - ulpravda.ru
Why MannKind Corporation stock is favored by top institutions2025 Biggest Moves & High Yield Equity Trading Tips - ulpravda.ru
Merck Looks To Buy Cancer Drugmaker Revolution Medicines: Report - Stocktwits
Boeing’s CEO Tells Staff ‘Important Work Ahead’ To Continue Its Turnaround: Report - Stocktwits
MannKind Rallies On Optimism Of Two Imminent Product Launches: Analyst Sees ‘Multiple Headwinds’ For Stock In 2026 - Stocktwits
How MannKind Corporation stock reacts to global recession fears2025 Volatility Report & Risk Managed Trade Strategies - Улправда
MannKind stock jumps on 2026 catalysts - Investing.com
Can MannKind Corporation stock deliver surprise earnings beatInsider Buying & Advanced Technical Analysis Signals - ulpravda.ru
MannKind Corp stock hits 52-week high at 6.33 USD - Investing.com
MannKind outlines 2026 growth drivers with key FDA decisions ahead - Investing.com
MannKind Provides Business Updates and 2026 Growth Drivers - Yahoo Finance
Leerink Partners Slashes MannKind Corporation’s (MNKD) Price Target to $7, Keeps a Buy Rating - MSN
Voya Investment Management LLC Sells 480,182 Shares of MannKind Corporation $MNKD - MarketBeat
Calamos Advisors LLC Acquires New Position in MannKind Corporation $MNKD - MarketBeat
MannKind Corp Is Suddenly Everywhere – Is MNKD the Next Sleeper Stock You’ll Regret Ignoring? - AD HOC NEWS
MannKind Corporation (MNKD) Secures FDA Approval for FUROSCIX Pediatric Use, Expanding Reach In Heart, Kidney Disease Care - Finviz
12 Best NASDAQ Stocks to Buy in 2026 - Insider Monkey
MannKind (MNKD) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
MNKD (MannKind) ROCE % : 17.64% (As of Sep. 2025) - GuruFocus
2.09%
0.48%
자본화:
|
볼륨(24시간):